- Home
- URGN vs MFH Comparison
URGN vs MFH Comparison
Compare URGN & MFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- MFH
- Stock Information
- Founded
- URGN 2004
- MFH 2011
- Country
- URGN United States
- MFH United States
- Employees
- URGN N/A
- MFH N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- MFH Finance: Consumer Services
- Sector
- URGN Health Care
- MFH Finance
- Exchange
- URGN Nasdaq
- MFH Nasdaq
- Market Cap
- URGN 465.9M
- MFH 382.7M
- IPO Year
- URGN 2017
- MFH N/A
- Fundamental
- Price
- URGN $9.67
- MFH $5.85
- Analyst Decision
- URGN Strong Buy
- MFH
- Analyst Count
- URGN 7
- MFH 0
- Target Price
- URGN $37.21
- MFH N/A
- AVG Volume (30 Days)
- URGN 499.1K
- MFH 64.6K
- Earning Date
- URGN 05-12-2025
- MFH 04-25-2025
- Dividend Yield
- URGN N/A
- MFH N/A
- EPS Growth
- URGN N/A
- MFH N/A
- EPS
- URGN N/A
- MFH N/A
- Revenue
- URGN $90,398,000.00
- MFH $716,863.00
- Revenue This Year
- URGN $38.65
- MFH N/A
- Revenue Next Year
- URGN $118.69
- MFH N/A
- P/E Ratio
- URGN N/A
- MFH N/A
- Revenue Growth
- URGN 9.29
- MFH 119.50
- 52 Week Low
- URGN $8.94
- MFH $1.03
- 52 Week High
- URGN $20.70
- MFH $8.86
- Technical
- Relative Strength Index (RSI)
- URGN 41.45
- MFH 54.51
- Support Level
- URGN $8.94
- MFH $5.10
- Resistance Level
- URGN $10.83
- MFH $5.78
- Average True Range (ATR)
- URGN 0.79
- MFH 0.64
- MACD
- URGN -0.07
- MFH 0.08
- Stochastic Oscillator
- URGN 29.67
- MFH 81.48
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.